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Background: To investigate the interaction of clinical characteristics with disease characterising parameters in
heart failure with preserved ejection fraction (HFpEF).
Methods and results
In the multicenter, randomized, placebo-controlled, double-blinded, Aldo-DHF trial investigating the effects of
spironolactone on exercise capacity (peakVO2) and diastolic function (E/e′) n=422 patients with HFpEF (age
67±8years, 52% females, LVEF 67±8%) were included. After multiple adjustment, higher age was signiﬁcantly
related to reduced peakVO2, and to increased E/e′, NT-proBNP, LAVI as well as LVMI (all pb0.05). Female gender
(pb 0.001), CAD (p=0.002), BMI (pb 0.001), sleep apnoea (p=0.02), and chronotropic incompetence (CI, p=
0.002) were related to lower peakVO2 values. Higher pulse pressure (p=0.04), lower heart rates (p=0.03), CI
(p=0.03) and beta-blocker treatment (p=0.001) were associated with higher E/e′. BMI correlated inversely
(p = 0.03), whereas atrial ﬁbrillation (p b 0.001), lower haemoglobin levels (p b 0.001), CI (p = 0.02), and
beta-blocker treatment (p b 0.001) were associated with higher NT-proBNP. After multiple adjustment for
demographic and clinical variables peakVO2 was not signiﬁcantly associated with E/e′ (r=+0.01, p=0.87),
logNT-proBNP (r=0.09, p=0.08), LAVI (r=+0.03, p=0.55), and LVMI (r=+0.05, p=0.37). The associations
of E/e′with logNT-proBNP (r=0.21, pb0.001), LAVI (r=+0.29, pb 0.001) and LVMI (r=0.09, p=0.06) were
detectable also after multiple adjustment.
Conclusions: Demographic and clinical characteristics differentially interact with exercise capacity, resting left
ventricular ﬁlling index, neurohumoral activation, and left atrial and ventricular remodelling in HFpEF. Exercise
intolerance in HFpEF ismulti-factorial and therapeutic approaches addressing exercise capacity should therefore
not only aim to improve single pathological mechanisms. Registration: ISRCTN94726526 (http://www.
controlled-trials.com), Eudra-CT-number 2006-002605-31.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.n Federal Ministry of Education and Research, clinical trial program Aldo-DHF [FKZ 01KG0506].
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Heart failure is amajor health problem in the community [1]. Current
data indicate that nowadays, more than 50% of patients with the clinical
syndrome of heart failure have a preserved left ventricular ejection
fraction (HFpEF) [2–4]. In contrast to earlier reports in which HFpEF
was considered to be more benign than heart failure with reduced
ejection fraction (HFrEF), recent data suggest that once hospitalized,
patients with HFpEF and those with HFrEF have a comparable prognosis
in terms ofmorbidity andmortality [2–4]. Despite increasing clinical and
economic relevance, no treatment has yet been shown to convincingly
reduce mortality in HFpEF [5–8]. This lack of evidence may in part be
founded in an incomplete understanding of the disease. There is some
evidence that exercise capacity (peakVO2), left ventricular ﬁlling index
(E/e′), neurohumoral activation (NT-proBNP) and parameters of left
atrial and left ventricular remodelling adequately reﬂect disease severity
and have the potential to serve as prognostic indicators in patients with
HFpEF [9,10]. They are part of the diagnostic algorithm for HFpEF
recommended by the ESC and they are used, alone or in combination,
as clinical endpoints in HFpEF studies [11]. However, it is a matter of
debate how demographic and clinical factors such as co-morbidities
impact on exercise capacity, diastolic function, neurohumoral acti-
vation, and left atrial and left ventricular remodelling in HFpEF and
whether these HFpEF characterizing key parameters independent of
demographic and clinical factors are correlated with each other.
Therefore, on the basis of HFpEF patients included in the Aldo-DHF
study, we aimed to analyse the impact of various demographic and
clinical factors on peakVO2, left ventricular ﬁlling index, NT-proBNP,
left atrial volume index and on left ventricular mass index. We also
investigated whether these disease speciﬁc key variables were
independent of demographic and clinical factors associated among
each other.2. Methods
The rationale and design of the Aldo-DHF trial have previously been described in
detail [12]. Aldo-DHF (http://www.controlled-trials.com, ISRCTN94726526/Eudra-CT-
number 2006-002605-31) was conducted in the context of the German Competence
Network Heart Failure (FKZ 01GI0205) and is funded by the German Federal Ministry of
Education and Research- Health Research (DLR Project Management (FKZ 01KG0506).2.1. Study objectives and primary endpoints of the Aldo-DHF trial
The primary objective of Aldo-DHF was to investigate the effects of the aldosterone
receptor blocker spironolactone (25mg/day vs. placebo) on functional and clinical endpoints
in patientswithheart failure, a preserved ejection fraction, but echocardiographic evidence of
diastolic dysfunction (i.e., diastolic heart failure/DHF), deﬁned as HFpEF with objective
evidence of diastolic dysfunction and evidence of impaired exercise capacity as measured
by spiroergometry [12]. In the Aldo-DHF trial, the change in exercise capacity (peakVO2 on
spiroergometry) and the change in E/e′ (ratio of peak early transmitral ventricular ﬁlling
velocity to early diastolic tissue Doppler velocity) from baseline to follow-up at 12 months
were chosen as co-primary endpoints.2.2. Trial design and patients
Aldo-DHF is a multicenter, prospective, randomized, placebo-controlled, double-
blind, parallel-group study, performed at 9 clinical trial sites in Germany and one trial
site in Austria. Patients with symptomatic HFpEF (NYHA II/III, LVEF ≥50%) and objective
evidence of diastolic dysfunction by echocardiography were recruited. Exclusion criteria
(e.g. relevant anaemia, end stage renal failure or signiﬁcant obstructive or restrictive
pulmonary diseases) were deﬁned to minimise confounding effects and assure
recruitment of a true and homogenous heart failure population [12]. Recruitment of 420
patients (210 patients per arm) was planned for statistical analysis, and recruitment
goals were reached in April 2011.
The study protocol and amendments were approved by the ethics committees and
responsible institutional review boards of all participating centres as well as the Federal
Institutes for Drugs and Medical Devices. All patients gave written informed consent
before any study related procedure was performed. The study strictly adhered to GCP
rules, and data management and monitoring, quality control, and statistical analysis was
performed at the Center for Clinical Trials Leipzig, Germany.2.3. Echocardiography
To ensure high quality and validity of echocardiographic data obtained in Aldo-DHF,
two national echo coordinators acted as blinded reference centres for all aspects related
to echocardiography. A ﬁnal Standard Operating Procedure (SOP) for obtaining all
echocardiographic parameters was provided and prior to starting recruitment, all
participating echocardiographers were trained and certiﬁed by the reference centres.
The protocol required that 2D andM-mode images and all calculationswere in accordance
with American Society of Echocardiography (ASE) guidelines [13,14]. Grading of diastolic
dysfunction was done as previously described [12,15]. As previously described we
noninvasively characterized the ventricular–arterial coupling index: arterial elastance
index (EaI)/ventricular elastance index ELVI = end-systolic volume index (ESVI)/stroke
volume index (SVI) [16].
2.4. Spiroergometry
The procedure of exercise testing was performed in accordance with recom-
mendations of the European Society of Cardiology [17]. A reference laboratory acted as
blinded core lab for all aspects related to cardiopulmonary exercise testing. Before starting
recruitment, an SOP for spiroergometry was released by the reference laboratory and all
investigators performing exercise testing were trained and certiﬁed by the core lab.
Validity criteria specify that each exercise test report must be conﬁrmed by the reference
centre.
Symptom-limited cardiopulmonary exercise testing on a bicycle ergometer started at
a work load of 20 Watts, followed by a stepwise 20 Watt increment every two minutes.
Heart rate, ST-segment changes and arrhythmias were continuously monitored via
standard 12-lead ECG. Blood pressure was recorded at rest and then every two minutes.
Ventilatory exchange (VE), oxygen uptake (VO2) and other cardiopulmonary variables
are acquired by averaging breath-by-breath measurements over 10 s intervals. Peak
heart rate and work load were recorded immediately upon the end of exercise. PeakVO2
was prospectively deﬁned as the maximum value of the last three 10 s averages during
exercise. Ventilatory anaerobic threshold is detected using the V-Slope method [18].
Chronotropic incompetence (CI) was deﬁned as a failure to achieve 80% of the maximum
age-predicted heart rate in patients without beta-blockers and to achieve 62% of the
maximum age-predicted heart rate in patients with beta-blockers [19,20].
2.5. Laboratory measurements
Blood sampleswere drawnafter 20min rest in lying position for analysis of laboratory
parameters. Samples were immediately cooled, centrifuged and processed for storage at
−80 °C. After thawing, N-terminal pro-brain-type-natriuretic-peptide (NT-proBNP) was
measured with a commercially available electrochemiluminescence immunoassay on an
Elecsys® Analyser (Roche Diagnostics GmbH, Mannheim, Germany).
2.6. Biometry
Data were presented as means and standard deviations or frequencies and
percentages as appropriate. Comparisons between patients in NYHA classes II and III
were carried out by the t test or Fisher's test, respectively (or Kendall's test for ordinal
categories). Relationships between predeﬁned general characteristics and peakVO2, E/e′
and NT-proBNP were examined by simple linear regression analyses for each predictor
variable, and by multiple regression including all predictors at once. Relationships
between peakVO2, E/e′ and NT-proBNPwere assessed by Pearson's correlation coefﬁcient
and analysis of variance. Partial correlations were controlled for age, sex, coronary heart
disease, hypertension, hyperlipidaemia, diabetes mellitus, cerebrovascular diasease,
peripheral arterial disease, COPD, atrial ﬁbrillation, history of depression, sleep apnoea,
BMI, mean arterial pressure, pulse pressure, heart rate, chronotropic incompetence,
ventricular–arterial coupling index, haemoglobin, eGFR, ACE inhibitor/angiotensin
receptor blocker, betablocker, and diuretic.
Data for NT-proBNP, were described by medians and inter-quartile ranges, and were
analyzed on a logarithmic scale. For the regression analyses of log NT-proBNP, results
were transformed back by the exponential function, yielding effect estimates in terms of
geometric mean ratios (instead of arithmetic mean differences). A two-sided p b 0.05
was considered statistically signiﬁcant. IBM SPSS version 20 was used as statistical
software.
3. Results
Between March 2007 and April 2011, n = 422 patients were
randomised into the trial. Baseline characteristics, results of exercise
testing as well as detailed echocardiographic measurements are shown
in Table 1.
Compared to patients with NYHA II, patients in NYHA III were older,
more obese, less frequently smoking, andmore frequently had a history
of hypertension and peripheral artery disease. They were more likely to
have peripheral edema and suffer from nycturia, paroxysmal nocturnal
dyspnea, and fatigue. Diastolic and pulse pressure were higher in NYHA
Table 1
Characteristics of the study cohort.
Variable All patients NYHA class II NYHA class III P-value
Number of subjects 422 363 59
Demography
Age [yr] 67±8 66±7 70± 8 0.001
Female sex 221 (52) 178 (49) 43 (73) 0.001
History
Hospitalisation for heart failure during past 12 months 156 (37) 132 (36) 24 (41) 0.56
Smoking 0.03
Never smoked 223 (53) 186 (51) 37 (63)
Former smoker 172 (41) 150 (41) 22 (37)
Current smoker 27 (6) 27 (7) 0 (0)
Coronary heart disease 170 (40) 144 (40) 26 (44) 0.57
Previous myocardial infarction 67 (16) 58 (16) 9 (15) 1.00
Previous coronary bypass 31 (7) 26 (7) 5 (9) 0.79
Hypertension 387 (92) 329 (91) 58 (98) 0.04
Hyperlipidaemia 273 (65) 236 (65) 37 (63) 0.77
Diabetes mellitus 70 (17) 59 (16) 11 (19) 0.71
Cerebrovascular disease 45 (11) 37 (10) 8 (14) 0.49
Peripheral arterial disease 17 (4) 11 (3) 6 (10) 0.02
COPD 14 (3) 10 (3) 4 (7) 0.12
Atrial ﬁbrillation 22 (5) 19 (5) 3 (5) 1.00
History of depression 47 (11) 40 (11) 7 (12) 0.82
Sleep apnoea 50 (12) 43 (12) 7 (12) 1.00
Physical examination
BMI [kg/m2] 28.9± 3.6 28.7± 3.6 30.2± 3.2 0.004
RR systolic [mmHg] 135± 18 135±18 136±21 0.62
RR diastolic [mmHg] 79±11 80±11 77± 11 0.04
MAP [mmHg] 98±12 98±12 96± 13 0.32
Puls pressure [mmHg] 56±15 55±15 60± 17 0.04
Heart rate on ECG [bpm] 65±13 65±13 67± 13 0.44
Signs/symptoms
Peripheral oedema 165 (39) 126 (35) 39 (66) b0.001
Nocturia 338 (80) 284 (78) 54 (92) 0.02
Paroxysmal nocturnal dyspnoea 67 (16) 49 (14) 18 (31) 0.002
Nocturnal cough 61 (15) 48 (13) 13 (22) 0.11
Fatigue 249 (59) 201 (55) 48 (81) b0.001
Laboratory
Sodium [mmol/L] 140± 3 140±3 141±3 0.20
Potassium [mmol/L] 4.2± 0.4 4.2± 0.4 4.2± 0.4 0.87
Total cholesterol [mg/dL] 195± 44 195±45 198±41 0.58
Haemoglobin [g/dL] 13.8± 1.2 13.9± 1.2 13.5± 1.1 0.02
eGFR [mL/min/1.73m2] 79±19 80±19 73± 19 0.006
Uric acid [mg/dL] 6.1± 1.6 6.1± 1.6 6.2± 1.6 0.55
NT-proBNP [ng/L] 158 (83–299) 156 (82–311) 171 (104–286) 0.71
Spiroergometry
Maximal workload [W] 100± 29 103±29 80± 20 b0.001
Duration of exercise [s] 540± 176 561±174 413±128 b0.001
RR systolic at rest [mmHg] 122± 18 121±18 123±19 0.50
RR systolic at maximal stress [mmHg] 169± 28 170±29 162±25 0.04
RR diastolic at rest [mmHg] 79±12 79±12 78± 13 0.29
RR diastolic at maximal stress [mmHg] 85±18 86±17 85± 19 0.71
Heart rate at rest [bpm] 70±13 70±13 70± 13 0.99
Heart rate at maximal stress [bpm] 117± 21 118±21 110±18 0.004
Chronotropic incompetence 25 (6) 22 (6) 3 (5) 1.00
VE at rest [L/min] 8.4± 2.4 8.4± 2.3 8.5± 2.9 0.71
VE at maximal stress [L/min] 45.7± 12.9 46.5± 13.0 40.6± 11.0 0.001
Peak VO2 [mL/min/kg] 16.4± 3.5 16.7± 3.4 14.4± 3.4 b0.001
Anaerobic threshold [W] 64±25 66±25 50± 19 b0.001
AT VO2 [mL/min/kg] 11.6± 3.2 11.8± 3.2 10.4± 3.0 0.002
VE/VCO2 Slope 30.3± 5.2 30.1± 4.8 31.8± 7.0 0.07
Borg scale 5.4± 3.7 5.3± 3.9 6.2± 2.7 0.07
RQ at rest 0.84± 0.07 0.84±0.08 0.85± 0.07 0.43
RQmax 1.11± 0.12 1.11±0.12 1.11± 0.12 0.95
RQmax post 1.38± 0.19 1.38±0.19 1.34± 0.16 0.12
Six-minute walk test
Walk distance [m] 530± 87 544±73 442±113 b0.001
Terminated before 6 min 8 (2) 2 (1) 6 (10) b0.001
Borg scale 3.1± 1.8 2.9± 1.6 4.3± 1.9 b0.001
Echocardiography
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Table 1 (continued)
Variable All patients NYHA class II NYHA class III P-value
LVEF [%] 67±8 67±8 69± 8 0.18
LVDED diameter (ED) [mm] 46.5± 6.2 46.8± 6.2 45.1± 6.2 0.06
LVDES diameter (ED) [mm] 25.5± 6.4 25.7± 6.6 24.3± 5.6 0.12
Ventricular-arterial coupling index 0.50± 0.17 0.51±0.17 0.47± 0.16 0.15
IV septum thickness [mm] 12.2± 1.8 12.2± 1.9 12.2± 1.6 0.96
Posterior wall thickness [mm] 11.5± 1.5 11.5± 1.5 11.6± 1.9 0.57
LV mass index [g/m2]
Men 117± 31 118±32 110±23 0.22
Women 101± 23 100±21 105±27 0.32
LAES [mm] 44.2± 5.7 44.1± 5.7 44.9± 5.7 0.35
LAVI [mL/m2] 28.0± 8.4 27.8± 8.2 29.2± 9.7 0.32
E velocity [cm/s] 73±19 73±19 74± 20 0.67
A velocity [cm/s] 83±18 82±18 85± 18 0.40
E/A 0.91± 0.33 0.91±0.32 0.91± 0.37 0.99
A duration [ms] 154± 32 153±31 158±38 0.42
IVRT [ms] 89±26 88±25 91± 28 0.42
Deceleration time [ms] 243± 63 242±63 247±59 0.61
Medial e′ velocity [cm/s] 5.9± 1.3 5.9± 1.4 5.9± 1.1 0.88
Medial a′ velocity [cm/s] 9.3± 1.8 9.3± 1.8 9.2± 2.1 0.86
E/e′ (medial) 12.8± 4.0 12.8± 4.2 12.7± 3.0 0.82
PVF systolic [cm/s] 58±12 58±12 58± 14 0.82
PVF diastolic [cm/s] 46±14 46±14 47± 15 0.79
PVA velocity [cm/s] 33±11 33±11 33± 8 0.94
PVA duration [ms] 125± 30 125±30 125±30 0.97
Flow propagation time [cm/s] 31±9 31±9 32± 11 0.50
Grade of diastolic dysfunction 0.42
I 307 (77) 262 (76) 45 (80)
II 86 (21) 75 (22) 11 (20)
III 4 (1) 4 (1) 0 (0)
IV 3 (1) 3 (1) 0 (0)
n.d. for atrial ﬁbrillation 22 19 3
Current medication
ACEI/ARB 325 (77) 277 (76) 48 (81) 0.51
Betablocker 302 (72) 256 (71) 46 (78) 0.29
Diuretic 227 (54) 186 (51) 41 (70) 0.01
Calcium antagonist 105 (25) 79 (22) 26 (44) 0.001
Anti-platelet agent 221 (52) 188 (52) 33 (56) 0.58
Anticoagulant 58 (14) 48 (13) 10 (17) 0.42
Lipid lowering drug 230 (55) 196 (54) 34 (58) 0.67
Allopurinol 40 (10) 32 (9) 8 (14) 0.24
Antidepressant 30 (7) 22 (6) 8 (14) 0.05
Quality of life
Responded to questionnaire 388 (92) 334 (92) 54 (92) 0.80
SF-36Physical Functioning scale 63±22 66±21 42± 20 b0.001
Symptoms of depression(PHQ-9 sum score) 5.6± 4.1 5.3± 4.0 7.4± 4.1 b0.001
Data are mean± SD or frequency (percentage), and exceptionally median (IQR) for NTproBNP.
P-values for comparison of NYHA classes II and III from t-test (quantities), Fisher's exact test (frequencies), or test for Kendall's tau-b (ordinal variables).
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levels as well as worse renal function in the more symptomatic
subgroup. We further observed substantial differences in exercise
parameters (spiroergometry and six-minute-walk-testing) between
the two groups: maximal and submaximal exercise capacity was
worse in NYHA III patients and this reduction was accompanied by
lower peak heart rate, peak systolic blood pressure, and worse
ventilation at peak exercise. They also performed worse in the six-
minute-walk test and subjectively felt more exhausted, as measured
on the Borg scale. Echocardiographic parameters did not differ
between NYHA II and NYHA III patients. Overall, mean LVEF was
normal (67 ± 8%) and diastolic dysfunction was present in all
patients with sinus rhythm, as per study protocol. The majority of
patients were treated with ACEI/ARBs, beta-blockers and diuretics.
More than 50% received anti-platelet agents and lipid lowering
drugs. Compared to NYHA II, patients with NYHA III were more
frequently treated with diuretics, calcium channel antagonists and
antidepressants, though prevalence of diagnosed depression did
not differ between groups.3.1. Association of peakVO2 with demographic and clinical characteristics
As shown in Table 2, in unadjusted (simple) regression analyses a
lower peakVO2 was signiﬁcantly related to higher age, female gender,
hypertension, diabetes mellitus, atrial ﬁbrillation, and sleep apnoea.
Also higher BMI, higher pulse pressure values, disturbed ventricular
vascular coupling, lower haemoglobin levels, beta-blocker and diuretics
intake were signiﬁcantly related to lower peakVO2 values. In multiple
adjusted regression analyses only higher age, female gender, coronary
artery disease, sleep apnoea, chronotropic incompetence, and higher
BMI remained signiﬁcantly related to lower peakVO2 values. The
association of peakVO2 with hypertension (p=0.06), diabetes mellitus
(p=0.05), and lower heart rate (p=0.05) was still detectable, albeit at
borderline statistical signiﬁcance.
3.2. Association of E/e′ with demographic and clinical characteristics
In unadjusted regression analyses, higher E/e′ values were
signiﬁcantly related to higher age, female gender and to a presence of
Table 2
Cross-sectional relationships of peakVO2 with general characteristics.
Associated difference in peakVO2 (spiroergometry)
Variable Unadjusted (simple regression) Adjusted (multiple regression)
Coefﬁcient (95% CI) P-value Coefﬁcient (95% CI) P-value
Age (per +10 years) –0.93 (–1.36 to –0.50) b0.001 –0.90 (–1.33 to –0.48) b0.001
Female sex –2.20 (–2.83 to –1.56) b0.001 –2.47 (–3.14 to –1.80) b0.001
Coronary heart disease –0.67 (–1.35 to +0.01) 0.05 –1.13 (–1.83 to –0.43) 0.002
Hypertension –1.72 (–2.92 to –0.52) 0.005 –1.12 (–2.28 to +0.04) 0.06
Hyperlipidaemia –0.25 (–0.95 to +0.45) 0.48 +0.21 (–0.47 to +0.89) 0.54
Diabetes mellitus –1.38 (–2.27 to –0.49) 0.002 –0.79 (–1.59 to 0.00) 0.05
Cerebrovascular disease +0.50 (–0.58 to 1.58) 0.36 +0.46 (–0.46 to +1.37) 0.33
Peripheral arterial disease –0.39 (–2.09 to +1.31) 0.65 –0.32 (–1.75 to +1.11) 0.66
COPD –0.23 (–2.10 to +1.63) 0.81 +0.44 (–1.19 to +2.06) 0.60
Atrial ﬁbrillation –1.72 (–3.22 to –0.23) 0.02 –0.62 (–2.00 to +0.77) 0.38
History of depression +0.05 (–1.01 to +1.12) 0.92 –0.29 (–1.20 to +0.62) 0.53
Sleep apnoea –1.22 (–2.25 to –0.19) 0.02 –1.10 (–1.99 to –0.21) 0.02
BMI (per +5 kg/m2) –1.60 (–2.04 to –1.15) b0.001 –1.58 (–2.01 to –1.16) b0.001
Mean arterial pressure (per +10 mmHg) +0.15 (–0.13 to +0.44) 0.30 –0.10 (–0.38 to +0.18) 0.49
Pulse pressure (per +10 mmHg) –0.24 (–0.45 to –0.02) 0.03 –0.10 (–0.32 to +0.12) 0.38
Heart rate on ECG (per +10 bpm) –0.25 (–0.51 to +0.01) 0.06 –0.25 (–0.49 to 0.00) 0.05
Chronotropic incompetence –1.42 (–2.83 to –0.01) 0.05 –1.92 (–3.14 to –0.70) 0.002
Ventricular-vascular coupling index (per +0.05) +0.13 (+0.03 to +0.23) 0.009 +0.04 (–0.04 to +0.13) 0.29
Haemoglobin (per +1 g/dL) +0.59 (+0.33 to +0.86) b0.001 +0.19 (–0.08 to +0.46) 0.16
eGFR (per +10 mL/min/1.73m2) +0.18 (0.00 to +0.36) 0.05 –0.09 (–0.25 to +0.07) 0.29
ACE inhibitor/angiotensin receptor blocker –0.80 (–1.59 to –0.01) 0.05 +0.50 (–0.30 to +1.30) 0.22
Betablocker –1.19 (–1.92 to –0.46) 0.001 –0.60 (–1.30 to +0.10) 0.10
Diuretic –1.41 (–2.06 to –0.75) b0.001 –0.17 (–0.80 to +0.46) 0.59
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values, lower resting heart rates, chronotropic incompetence, lower
haemoglobin levels, impaired renal function and the intake of ACE
inhibitors, beta-blockers or diureticswere signiﬁcantly related to higher
E/e′ values. Higher BMI was only by trend (p=0.09) associated with
higher E/e′. In multiple adjusted regression analyses only higher age,
female gender, higher pulse pressure values as well as a lower resting
heart rate, chronotropic incompetence, and beta-blocker intake
remained signiﬁcantly related to higher E/e′ values.Table 3
Cross-sectional relationships of E/e′with general characteristics.
Associated difference in E/e′
Variable Unadjusted (simple regressi
Coefﬁcient (95% CI)
Age (per +10 years) +1.05 (+0.55 to +1.55)
Female sex +1.23 (+0.47 to +2.00)
Coronary heart disease +0.45 (–0.33 to +1.24)
Hypertension +1.83 (+0.44 to +3.21)
Hyperlipidaemia +0.66 (–0.15 to +1.46)
Diabetes mellitus +1.18 (+0.15 to +2.21)
Cerebrovascular disease +0.83 (–0.42 to +2.08)
Peripheral arterial disease +0.21 (–1.75 to +2.17)
COPD +0.43 (–1.73 to +2.58)
Atrial ﬁbrillation +0.31 (–1.43 to +2.04)
History of depression +0.26 (–0.96 to +1.49)
Sleep apnoea –0.56 (–1.75 to +0.63)
BMI (per +5 kg/m2) +0.47 (–0.07 to +1.01)
Mean arterial pressure (per +10 mmHg) –0.15 (–0.48 to +0.18)
Pulse pressure (per +10 mmHg) +0.47 (+0.22 to +0.72)
Heart rate on ECG (per +10 bpm) –0.47 (–0.77 to –0.17)
Chronotropic incompetence +1.93 (+0.31 to +3.56)
Ventricular-arterial coupling index (per +0.05) –0.03 (–0.14 to +0.09)
Haemoglobin (per +1 g/dL) –0.45 (–0.76 to –0.14)
eGFR (per +10 mL/min/1.73m2) –0.24 (–0.44 to –0.03)
ACE inhibitor/angiotensin receptor blocker +1.05 (+0.14 to +1.96)
Betablocker +2.28 (+1.45 to +3.10)
Diuretic +1.50 (+0.74 to +2.26)3.3. Association of NT-proBNP with demographic and clinical characteristics
As shown in Table 4, in simple regression analyses higher NT-proBNP
values were signiﬁcantly related to higher age, coronary artery disease,
and to a presence of atrial ﬁbrillation. Lower BMI, lower haemoglobin
levels and impaired renal function, higher pulse pressure values, the
intake of beta-blockers and also of diuretics were signiﬁcantly related
to higher NT-proBNP levels. A trend was seen for the association to
sleep apnoea (p=0.05), hypertension (p=0.08) and cerebrovascular(echocardiography)
on) Adjusted (multiple regression)
P-value Coefﬁcient (95% CI) P-value
b0.001 +0.73 (+0.18 to +1.28) 0.009
0.002 +1.18 (+0.30 to +2.05) 0.008
0.26 –0.11 (–1.02 to +0.80) 0.81
0.01 +0.37 (–1.15 to +1.88) 0.64
0.11 +0.18 (–0.70 to +1.07) 0.69
0.03 +0.81 (–0.23 to +1.84) 0.13
0.19 +0.82 (–0.38 to +2.01) 0.18
0.84 +0.59 (–1.27 to +2.46) 0.53
0.70 +0.03 (–2.09 to +2.14) 0.98
0.73 +0.68 (–1.12 to +2.49) 0.46
0.67 +0.44 (–0.74 to +1.63) 0.47
0.36 –0.32 (–1.48 to +0.84) 0.59
0.09 +0.45 (–0.10 to +1.00) 0.11
0.38 –0.01 (–0.38 to +0.36) 0.97
b0.001 +0.30 (+0.01 to +0.59) 0.04
0.002 –0.36 (–0.68 to –0.04) 0.03
0.02 +1.74 (+0.15 to +3.33) 0.03
0.65 0.00 (–0.11 to+0.11) 1.00
0.005 –0.09 (–0.45 to +0.26) 0.60
0.02 –0.02 (–0.23 to +0.20) 0.89
0.02 +0.14 (–0.90 to +1.18) 0.79
b0.001 +1.59 (+0.67 to +2.50) 0.001
b0.001 +0.44 (–0.38 to +1.27) 0.29
Table 4
Cross-sectional relationships of NT-proBNP with general characteristics.
Associated ratio in NT-proBNP
Variable Unadjusted (simple regression) Adjusted (multiple regression)
Coefﬁcient (95% CI) P-value Coefﬁcient (95% CI) P-value
Age (per +10 years) ×1.63 (1.45 to 1.85) b0.001 ×1.31 (1.16 to 1.49) b0.001
Female sex ×1.10 (0.90 to 1.34) 0.36 ×0.89 (0.73 to 1.08) 0.24
Coronary heart disease ×1.29 (1.05 to 1.58) 0.02 ×1.18 (0.96 to 1.45) 0.12
Hypertension ×1.37 (0.96 to 1.97) 0.08 ×1.01 (0.73 to 1.42) 0.93
Hyperlipidaemia ×1.02 (0.82 to 1.26) 0.87 ×0.94 (0.77 to 1.14) 0.53
Diabetes mellitus ×0.80 (0.62 to 1.05) 0.11 ×0.81 (0.65 to 1.02) 0.07
Cerebrovascular disease ×1.34 (0.97 to 1.85) 0.08 ×1.15 (0.88 to 1.49) 0.31
Peripheral arterial disease ×1.03 (0.61 to 1.85) 0.91 ×1.03 (0.67 to 1.58) 0.89
COPD ×0.78 (0.44 to 1.37) 0.38 ×0.74 (0.46 to 1.19) 0.21
Atrial ﬁbrillation ×6.04 (3.90 to 9.37) b0.001 ×5.87 (3.89 to 8.90) b0.001
History of depression ×0.79 (0.58 to 1.08) 0.14 ×0.90 (0.70 to 1.17) 0.43
Sleep apnoea ×0.74 (0.54 to 1.00) 0.05 ×0.78 (0.60 to 1.01) 0.06
BMI (per +5 kg/m2) ×0.83 (0.72 to 0.96) 0.01 ×0.87 (0.77 to 0.98) 0.03
Mean arterial pressure (per +10 mmHg) ×0.96 (0.88 to 1.04) 0.30 ×1.03 (0.95 to 1.12) 0.42
Pulse pressure (per +10 mmHg) ×1.07 (1.00 to 1.14) 0.04 ×1.02 (0.96 to 1.09) 0.53
Heart rate on ECG (per +10 bpm) ×0.94 (0.87 to 1.02) 0.16 ×0.93 (0.87 to 1.00) 0.05
Chronotropic incompetence ×1.43 (0.94 to 2.18) 0.10 ×1.51 (1.06 to 2.14) 0.02
Ventricular-arterial coupling index (per +0.05) ×1.00 (0.97 to 1.03) 0.93 ×1.01 (0.99 to 1.03) 0.43
Haemoglobin (per +1 g/dL) ×0.83 (0.77 to 0.90) b0.001 ×0.85 (0.79 to 0.92) b0.001
eGFR (per +10 mL/min/1.73m2) ×0.89 (0.85 to 0.94) b0.001 ×0.95 (0.91 to 1.00) 0.05
ACE inhibitor/angiotensin receptor blocker ×1.11 (0.88 to 1.41) 0.39 ×0.92 (0.73 to 1.15) 0.46
Betablocker ×2.03 (1.64 to 2.50) b0.001 ×1.65 (1.35 to 2.02) b0.001
Diuretic ×1.34 (1.10 to 1.64) 0.004 ×1.20 (1.00 to 1.44) 0.05
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presence of atrial ﬁbrillation, lower resting heart rate (p = 0.05),
chronotropic incompetence, lower BMI, lower haemoglobin levels and,
by trend, an impaired renal function (p=0.05) as well as beta-blocker
and diuretics intake (p=0.05) remained signiﬁcantly related to higher
NT-proBNP levels.
3.4. Association of LAVI with demographic and clinical characteristics
As shown in Table 5, in simple regression analyses higher values
of LAVI were signiﬁcantly related to higher age, female gender,
hypertension, atrial ﬁbrillation, pulse pressure, and to the intake of
ACE inhibitors/angiotensin receptor blockers, beta-blockers as wellTable 5
Cross-sectional relationships of left atrial volume index with general characteristics.
Associated difference in left at
Variable Unadjusted (simple regression
Coefﬁcient (95% CI)
Age (per +10 years) +2.40 (+1.37 to +3.44)
Female sex −2.88 (−4.47 to−1.29)
Coronary heart disease +1.25 (−0.39 to +2.89)
Hypertension +3.05 (+0.14 to +5.95)
Hyperlipidaemia −0.20 (−1.89 to +1.49)
Diabetes mellitus −0.34 (−2.50 to +1.83)
Cerebrovascular disease +0.91 (−1.69 to +3.52)
Peripheral arterial disease +3.65 (−0.43 to +7.73)
COPD +1.45 (−3.04 to +5.95)
Atrial ﬁbrillation +13.48 (+10.10 to +16.86)
History of depression +0.37 (−2.21 to +2.96)
Sleep apnoea +1.71 (−0.77 to +4.20)
BMI (per +5 kg/m2) −0.06 (−1.19 to +1.07)
Mean arterial pressure (per +10 mmHg) +0.66 (−0.03 to +1.34)
Pulse pressure (per +10 mmHg) +0.76 (+0.24 to +1.28)
Heart rate on ECG (per +10 bpm) −0.50 (−1.12 to +0.13)
Chronotropic incompetence +2.33 (−1.08 to +5.73)
Ventricular-arterial coupling index (per +0.05) +0.16 (−0.07 to +0.40)
Haemoglobin (per +1 g/dL) −0.33 (−0.99 to +0.32)
eGFR (per +10 mL/min/1.73m2) +0.02 (−0.41 to +0.46)
ACE inhibitor/angiotensin receptor blocker +2.58 (+0.68 to +4.49)
Betablocker +3.38 (+1.62 to +5.14)
Diuretic +2.11 (+0.50 to +3.71)as of diuretics. A trend was seen for the association to the mean
arterial pressure (p = 0.06), and peripheral arterial disease (p =
0.08). In multiple regression analyses higher age, female gender,
the presence of atrial ﬁbrillation, lower resting heart rate, higher
mean arterial pressure, lower haemoglobin levels as well as the
intake of ACE inhibitors/angiotensin receptor blockers, and beta-
blockers were related to higher LAVI values.
3.5. Association of LVMI with demographic and clinical characteristics
As shown in Table 6, in simple regression analyses higher values
of LVMI were signiﬁcantly related to higher age, female gender,
cerebrovascular disease, higher pulse pressure, lower resting heart rate,rial volume index
) Adjusted (multiple regression)
P-value Coefﬁcient (95% CI) P-value
b0.001 +1.58 (+0.53 to +2.63) 0.003
b0.001 −3.49 (−5.18 to−1.80) b0.001
0.14 −0.17 (−1.94 to +1.59) 0.85
0.04 −0.53 (−3.45 to +2.39) 0.72
0.82 −0.76 (−2.47 to +0.94) 0.38
0.76 −0.83 (−2.82 to +1.16) 0.41
0.49 −0.06 (−2.36 to +2.24) 0.96
0.08 +3.07 (−0.51 to +6.65) 0.09
0.53 +2.58 (−1.50 to +6.65) 0.22
b0.001 +15.02 (+11.56 to +18.49) b0.001
0.78 +0.77 (−1.53 to +3.07) 0.51
0.18 +1.24 (−0.99 to +3.46) 0.28
0.92 −0.63 (−1.69 to +0.43) 0.25
0.06 +0.83 (+0.12 to +1.54) 0.02
0.004 +0.42 (−0.14 to +0.97) 0.14
0.12 −1.05 (−1.66 to−0.44) 0.001
0.18 +2.13 (−0.92 to +5.19) 0.17
0.18 +0.11 (−0.09 to+ 0.32) 0.28
0.32 −0.96 (−1.63 to−0.28) 0.006
0.91 +0.32 (−0.09 to +0.73) 0.12
0.008 +2.14 (+0.12 to +4.16) 0.04
b0.001 +2.20 (+0.44 to +3.97) 0.01
0.01 +1.35 (−0.24 to +2.94) 0.10
Table 6
Cross-sectional relationships of left ventricular mass index with general characteristics.
Associated difference in left ventricular mass index
Variable Unadjusted (simple regression) Adjusted (multiple regression)
Coefﬁcient (95% CI) P-value Coefﬁcient (95% CI) P-value
Age (per +10 years) +3.93 (+0.42 to +7.44) 0.03 +4.48 (+0.69 to +8.28) 0.02
Female sex −16.20 (−21.34 to−11.06) b0.001 −16.44 (−22.47 to−10.41) b0.001
Coronary heart disease +2.41 (−3.06 to +7.87) 0.79 −7.04 (−13.37 to−0.71) 0.03
Hypertension +5.37 (−4.34 to +15.07) 0.28 −1.74 (−12.18 to +8.71) 0.75
Hyperlipidaemia +3.44 (−2.16 to +9.04) 0.23 +4.08 (−2.04 to +10.20) 0.19
Diabetes mellitus +1.96 (−5.24 to +9.16) 0.59 −0.12 (−7.26 to +7.02) 0.97
Cerebrovascular disease −9.56 (−18.19 to−0.93) 0.03 −10.83 (−19.09 to−2.58) 0.01
Peripheral arterial disease +7.89 (−6.11 to +21.90) 0.27 +7.76 (−5.41 to +20.94) 0.25
COPD −8.89 (−23.82 to +6.05) 0.24 −9.99 (−24.57 to +4.60) 0.18
Atrial ﬁbrillation −0.25 (−12.57 to +12.07) 0.97 +6.79 (−5.80 to +19.39) 0.29
History of depression +2.58 (−5.93 to +11.10) 0.55 +4.86 (−3.32 to +13.03) 0.24
Sleep apnoea −0.11 (−8.40 to +8.18) 0.98 −1.67 (−9.70 to +6.35) 0.68
BMI (per +5 kg/m2) +1.26 (−2.48 to +5.01) 0.51 +0.14 (−3.66 to +3.93) 0.94
Mean arterial pressure (per +10 mmHg) +1.83 (−0.45 to +4.11) 0.12 −0.06 (−2.61 to +2.49) 0.96
Pulse pressure (per +10 mmHg) +3.67 (+1.95 to +5.39) b0.001 +2.83 (+0.85 to +4.81) 0.005
Heart rate on ECG (per +10 bpm) −4.13 (−6.25 to−2.00) b0.001 −3.19 (−5.43 to−0.95) 0.005
Chronotropic incompetence +9.51 (−1.81 to +20.82) 0.10 +5.82 (−5.13 to +16.77) 0.30
Ventricular-arterial coupling index (per +0.05) +0.54 (−0.24 to +1.32) 0.18 +0.22 (−0.52 to+ 0.97) 0.56
Haemoglobin (per +1 g/dL) +2.85 (+0.67 to +5.02) 0.01 +0.16 (−2.27 to +2.59) 0.90
eGFR (per +10 mL/min/1.73m2) +1.30 (−0.13 to +2.73) 0.08 +1.31 (−0.15 to +2.76) 0.08
ACE inhibitor/angiotensin receptor blocker +4.79 (−1.57 to +11.14) 0.14 +1.73 (−5.45 to +8.91) 0.64
Betablocker +4.63 (−1.31 to +10.57) 0.13 +2.07 (−4.25 to +8.38) 0.52
Diuretic +4.14 (−1.23 to +9.50) 0.13 +4.72 (−0.96 to +10.39) 0.10
414 F. Edelmann et al. / International Journal of Cardiology 169 (2013) 408–417and lower haemoglobin levels. In multiple regression analyses higher
age, female gender, cerebrovascular disease, higher pulse pressure, and
lower resting heart rate, remained to be related to higher LVMI values.
3.6. Interrelation of peakVO2, E/e′, NT-proBNP, LAVI, and LVMI
Table 7 is shown the unadjusted (bivariate) as well as the adjusted
(partial) correlations of peakVO2, E/e′, NT-proBNP, LAVI, and LVMI
among each other. In bivariate correlation analyses peakVO2 was
signiﬁcantly associated with E/e′ and log10 NT-proBNP, but not with
LAVI and LVMI. Unadjusted, E/e′ was signiﬁcantly related to all other
parameters. After multiple adjustment also the association of peakVO2
with E/e′ and log10 NT-proBNP lost their signiﬁcance. After multiple
adjustment the association of E/e′ with log10 NT-proBNP, LAVI, and
LVMI (by trend) and also the association of LAVI and LVMI remained
to be signiﬁcant.
4. Discussion
Aldo-DHF is the ﬁrst large randomised, controlled HFpEF trial with
rigorous inclusion criteria for cardiac remodelling/diastolic dysfunction,
and comprehensive phenotyping of all patients. Here, we report baseline
data from the n=422 patients recruited into the trial and analyzed the
association of demographic and clinical variables with parameters of
exercise capacity (peakVO2), parameters of diastolic dysfunction (E/e′),Table 7
Bivariate (above diagonal) and partial (below diagonal) correlations of the endpoints.
PeakVO2 E/e′
Pearson's correlation coefﬁcient (P-value)
PeakVO2 – −0.16 (0.001)
E/e′ +0.01 (0.87) –
Log10 NTproBNP −0.09 (0.08) +0.21 (b0.001)
LAVI +0.03 (0.55) +0.29 (b0.001)
LVMI +0.05 (0.37) +0.09 (0.06)
Partial correlation coefﬁcient (P-value)
Partial correlationswere controlled for age, sex, coronary heart disease, hypertension, hyperlipid
ﬁbrillation, history of depression, sleep apnoea, BMI,mean arterial pressure, pulse pressure, hear
ACE inhibitor/angiotensin receptor blocker, betablocker, diuretic.neurohumoral activation (NT-proBNP) as well as left atrial and left
ventricular remodelling (LAVI/LVMI). Our study has the following main
ﬁndings:
1) Age is the only factor that negatively impacted on all parameters:
peakVO2, E/e′, NT-proBNP, LAVI, and LVMI.
2) Besides older age and female gender, isolated co-morbidities and
chronotropic incompetence negatively impacted on peakVO2
whereas higher pulse pressure values, lower resting heart rates,
chronotropic incompetence and beta-blocker treatment were
associated with an impaired resting diastolic function.
3) Higher BMI was associated with lower levels of NT-proBNP. Besides
higher age, presence of atrial ﬁbrillation, chronotropic incompetence,
lower haemoglobin levels, diuretic, and beta-blocker treatment were
also independently related to higher NT-proBNP levels.
4) Albeit signiﬁcant, unadjusted correlations between peakVO2, E/e′
and NT-proBNP were at best moderate and LAVI and LVMI were
not related to exercise capacity. After multiple adjustment also
the associations of peakVO2 with E/e′ and NT-proBNP lost their
signiﬁcance.
4.1. Population studied
We included 422 patients with symptoms of heart failure, preserved
ejection fraction and echocardiographically proven diastolic dysfunction.Log10 NT-proBNP LAVI LVMI
−0.16 (0.001) −0.02 (0.66) +0.08 (0.09)
+0.31 (b0.001) +0.31 (b0.001) +0.12 (0.02)
– +0.43 (b0.001) +0.11 (0.03)
+0.24 (b0.001) – +0.29 (b0.001)
+0.07 (0.18) +0.20 (b0.001) –
aemia, diabetesmellitus, cerebrovascular diasease, peripheral arterial disease, COPD, atrial
t rate, chronotropic incompetence, ventricular-arterial coupling index, haemoglobin, eGFR,
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studies,which are predominantly female, of older age andwith numerous
co-morbidities [6–8,10,15,21,22]. As a consequence of the complex study
design also addressing safety aspects some co-morbidities (e.g. diabetes
mellitus, atrial ﬁbrillation) were underrepresented in the Aldo-DHF trial.
However, when compared to prior large interventional trials, patients
were of similar age (CHARM-Preserved) or younger (I-PRESERVE) and,
as shown by the distribution of NYHA functional class and NT-pro BNP
levels in our cohort, rather representative of an out-patient, clinically
stable HFpEF cohort [15,23]. The vigorous in- and exclusion criteria (e.g.
anaemia, severe renal dysfunction and pulmonary disorders) also for
safety aspects and the need for repeated spiroergometric measurements
may have refrained older, more co-morbid and sicker patients from
participating in Aldo-DHF. However, advanced HFpEF in elderly patients
is associated with a high rate of non-cardiac death [24]. Therefore,
interventions targeted to the cardiovascular system in symptomatic
HFpEF may be more effective in earlier stages of the disease and at a
younger age range [15,25].
4.2. Role of diastolic dysfunction
In Aldo-DHF all patients underwent detailed echocardiography
including comprehensive evaluation of diastolic function according to
current diagnostic guidelines [11]. This is a major step forward in
comparison to previous and ongoing interventional studies, where a
signiﬁcant number of patients do not have diastolic dysfunction which
is believed to be causative in HFpEF [26,27]. Nevertheless, it has not
been examined up to now,whether amore speciﬁc deﬁnition of patients
beyond their clinical presentation and conﬁrming a normal or preserved
left ventricular ejection fraction is really superior and improves the
“correct” identiﬁcation of patients with HFpEF [11,28].
4.3. Impacting factors on exercise capacity
In our study, older age, female gender, presence of CAD, higher BMI,
sleep apnoea and chronotropic incompetence remained signiﬁcant
predictors of impaired exercise capacity after multivariate adjustment.
These results underline the crucial role of ageing with the incremental
impact of co-morbidities as a major determinant in HFpEF patients [29].
Hypertension and diabetes mellitus only tended to be independently
related to peakVO2 in our cohort. This is complementary to reports
investigating exercise performance in patients with diastolic dysfunction
and suggests that there are similarities in exercise limiting factors
between diastolic dysfunction and HFpEF [30]. It has recently been
shown that in HFpEF comorbidities relevantly impact symptoms and
prognosis [24,31]. The lack of an independent effect of hypertension and
diabetes in our study may be explained by the high prevalence of
hypertension and the relatively small number of patients with diabetes
[30]. Chronotropic incompetence was, albeit less frequent in our cohort,
also strongly related to exercise capacity. Because there is evidence that
chronotropic incompetence negatively interfere also with prognosis,
this important subgroup of patients need to be identiﬁed and treated in
a more specialized manner [23].
4.4. Impacting factors on resting left ventricular ﬁlling index
E/e′ is an accepted continuous marker of progressive diastolic
dysfunction, an indicator of left-ventricular end-diastolic pressure and
hence recommended for diagnosing HFpEF, either alone or in conjunction
with other parameters [11,32,33]. Moreover, E/e′ provides prognostic
information in patients at risk for and with HFpEF [9,34]. However, there
is only limited evidence regarding the independent interference of
demographic and clinical factors with E/e′ in HFpEF. In our study, higher
age, female gender, pulse pressure, lower resting heart rates, chronotropic
incompetence and beta-blocker therapywere independent of other factors
associatedwith higher E/e′ values. These results further substantiate recentdata showing that the presence of chronotropic incompetence further
increases morbidity in patients with HFpEF [35]. In addition, in the
ELANDD trial, heart rate reduction due to nebivolol resulted in a decrease
of exercise capacity in patients with HFpEF [36]. However, our patients
did not suffer from increased heart rates, therefore the negative association
also between resting heart rates, beta-blocker treatment and resting left
ventricular ﬁlling index might be of limited generalizability. Furthermore,
data from SENIORS suggest a prognostic beneﬁt due to beta-blockers also
in HFpEF [37]. Therefore, the role of heart rate and the effects of changes
of heart rate also on diastolic function need to be more comprehensively
addressed in future studies.
4.5. Impacting factors on neurohumoral activation
NT-proBNP values of patients included into the Aldo-DHF trial
were lower than reported in I-PRESERVE [38]. However, compared to
I-PRESERVE our patients were younger, had to a large extent a preserved
renal function andwere found to be in lower NYHA classes. Furthermore,
in Aldo-DHF only 5% of patients presented with atrial ﬁbrillation
(26% in I-PRESERVE) and no one with pulmonary congestion (39% in
I-PRESERVE). In line with data from I-PRESERVE, we found a large
number of bivariate associations of demographic and clinical variables
with NT-proBNP. In addition, we found that atrial ﬁbrillation, lower
eGFR, lower BMI and lower haemoglobin levels were associated with
higher NT-proBNP values and were able to conﬁrm that lower heart
rate and beta-blocker intake were also independently related to higher
NT-proBNP values in our sample of predominantly NYHA II HFpEF
patients. This, again, strengthens the hypothesis that lower heart rates
are not automatically beneﬁcial and consequently heart rate reduction
in HFpEF, at least in patients with adequately controlled heart rates as
in our cohort, will not necessarily result in a clinical improvement
[36,38]. The role of NT-proBNP in HFpEF is probably less prominent
than in HFrEF and newer cardiac markers (e. g., MR-proADM, GDF-15)
may play a more important role [39,40].
4.6. Association of maximal exercise capacity, resting left ventricular ﬁlling
index, neurohumoral activation and left atrial and left ventricular remodeling
Whether peakVO2, E/e′, NT-proBNP, LAVI, and LVMI are correlated
among each other in patients with HFpEF has not been investigated so
far. We found that, albeit signiﬁcant, bivariate associations among
parameters were moderate. Key parameters of LA and LV remodelling
were related to E/e′ and NT-proBNP. Of particular interest, the
unadjusted association of maximal exercise capacity with resting E/e′
and NT-proBNP was explained by variables included into multivariate
model, the signiﬁcance was lost after controlling for co-variates. The
ﬁnding that resting diastolic function aswell as neurohumoral activation
was not independently linked to exercise capacity strongly supports the
concept of symptomatic HFpEF as a multicausative disease. It is known
that independent of age and gender, peakVO2 is reduced in HFpEF
[10,15,41-43]. However, there is only little evidence regarding the
association of maximal exercise capacity with diastolic function and no
evidence regarding the impact of neurohumoral activation on maximal
exercise capacity in HFpEF. Guazzi et al. demonstrated that severity of
diastolic dysfunction reﬂects the decrease in exercise capacity in HFpEF
[44]. In an interventional study in HFpEF we were able to show that an
improvement in exercise capacity was associated with an improvement
in diastolic function whereas NT-proBNP levels remained unchanged
[15]. In contrast, our data suggest that physical limitation in HFpEF
cannot easily be explained by resting diastolic function or measurable
neurohumoral activation. Exercise intolerance in HFpEF is multi-
factorial and therapeutic approaches addressing exercise capacity should
therefore not only aim to improve single pathological mechanisms. Our
data further suggest that besides parameters recommended in current
diagnostic guidelines, demographic and other clinical variables must be
carefully considered for correct diagnosing of HFpEF patients [11,45].
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Thus far, Aldo-DHF is the largest prospective randomised
multicentre trial with HFpEF patients and echocardiographically proven
diastolic dysfunction. The standardized evaluation of exercise capacity
by a core-lab-certiﬁed study centres in all patients is another advantage.
The geographic distribution of study sites (only Germany and Austria)
with only Caucasians included might limit the possibility to transfer
study results to other ethnicities and countries.
We predominantly included NYHA II patients and due to design
aspects some co-morbidities such as diabetes mellitus and atrial
ﬁbrillation were underrepresented wherefore our results cannot easily
extrapolated to older, more co-morbid and clinically more affected
patients with HFpEF. Additionally, the need for bicycle exercise testing
may have refrained a relevant number of patientswith a general inability
for maximal exercise testing (e.g. for orthopedic reasons) from
participation in the Aldo-DHF trial which reduces the generalizability
of our ﬁndings. Diastolic function was investigated only using the
surrogate measure left ventricular ﬁlling index and only under resting
conditions. Exercise measurements of diastolic function might have
had more explanatory power in this ambulatory and clinically stable
patient cohort since diastolic LV stiffness and the rise in LV ﬁlling
pressures during exercise are known to contribute to the reduction in
tolerance in patients with HFpEF [46]. Furthermore, E/e′ as a single
surrogate measure of diastolic function does not adequately reﬂect left
ventricular end diastolic volume. Furthermore, other factors with
known potential to inﬂuence exercise capacity or diastolic function
such as endothelial function were not investigated in the present study.4.8. Clinical implications
Multiple factors affect exercise capacity in HFpEF and the reduced
exercise capacity can only be partly explained by changes e. g. in resting
diastolic function or measures of LV remodelling and neurohormonal
activation. Co-morbidities, which have been shown to affect functional
status in HFpEF to a larger degree than in HFrEF, need to be more
thoroughly and systematically investigated when considering the
diagnosis HFpEF [31]. Our group and others recently showed that
exercise training not only improves central hemodynamics or diastolic
function, but also peak exercise capacity which probably is explained by
co-affecting of non-cardiac alterations like peripheral muscle function
[15,47]. Treatment options for HFpEF should therefore not only aim to
improve diastolic dysfunction and to reverse left ventricular remodelling,
but also address the complex non-cardiac pathophysiology of the disease.5. Conclusion
In this so far largest comprehensively characterized cohort of HFpEF
patients demographic and clinical characteristics differentially interact
with exercise capacity, resting left ventricular ﬁlling index, neurohumoral
activation, left atrial and left ventricular remodelling. Exercise capacity
correlated with left ventricular ﬁlling index and neurohumoral
activation, but these correlations were signiﬁcantly attenuated after
multiple adjustments. Exercise intolerance in HFpEF is multi-factorial
and therapeutic approaches addressing exercise capacity should
therefore not only aim to improve single pathological mechanisms.References
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